trending Market Intelligence /marketintelligence/en/news-insights/trending/lv1sc4bbgcvjpflgt37svq2 content esgSubNav
In This List

European regulator maintains rejection of PharmaMar blood cancer drug

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


European regulator maintains rejection of PharmaMar blood cancer drug

The European Medicines Agency maintained its negative opinion on Pharma Mar SA's blood cancer drug Aplidin.

In December 2017, the agency's Committee for Medicinal Products for Human Use rejected Pharma Mar's application to market the drug, also known as plitidepsin, as a treatment for multiple myeloma. The company requested that the committee revisit its decision in January.

Madrid-based Pharma Mar develops anti-cancer drugs derived from marine organisms.

Multiple myeloma is a type of blood cancer that occurs in the white blood cells and accumulates in the bone marrow.